SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02865304

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative Metastatic Breast Cancer Patients

The purpose of the present study was to prospectively evaluate the efficacy and safety of endostar, a recombinant product of endostatin, combined with taxane-based regimens for HER-2 negative metastatic breast cancer (MBC) patients.

NCT02865304 Angiogenesis Breast Cancer
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

1 Interventions

Name: endostar

Type: Drug
Group Labels: 1

endostar; taxane

Primary Outcomes

Measure: overall response rate

Time: one year

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 P125A

Regarding breast cancer, in vivo studies showed that the combination of paclitaxel and P125A-endostatin inhibited mammary cancer growth, delayed the onset of multifocal mammary adenocarcinomas, decreased tumor angiogenesis, increased the survival of treated mice in the prevention model, and inhibited lung and lymph node metastasis in the intervention model. --- P125A ---

HPO Nodes